Last reviewed · How we verify

Acid Reflux Relief (Sodium Phosphate, Dibasic, Heptahydrate)

Pfizer · FDA-approved approved Quality 44/100

Sodium Phosphate, Dibasic, Heptahydrate is a marketed drug by Pfizer Inc. It is used to preserve purity and is taken under the tongue before meals or as needed. The exact mechanism of action is not specified on Wikipedia. This drug has 2 trials and 6 publications. It is a significant commercial entity with $63.6B in revenue. There is limited information available on its clinical differentiation and pipeline developments.

At a glance

Generic nameSodium Phosphate, Dibasic, Heptahydrate
SponsorPfizer
Drug classNon-Standardized Plant Allergenic Extract [EPC]
TargetCarbonic anhydrase 4
PhaseFDA-approved
First approval1983

Approved indications

Common side effects

Drug interactions

Key clinical trials

Patents

PatentExpiryType

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results
FDA Orange BookPatents + exclusivity

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: